$27.14
-0.34 (-1.24%)
U News14 articles
Unity's AI Ad Engine Drives Revenue Growth, But Impairment Charge Weighs on Earnings
Unity Software posted a 17% revenue increase in Q1 2026, fueled by its AI-powered ad engine, but a $279 million impairment charge widened its net loss to $347 million.
Wall Street Extends Slide as Oil Spike, Tech Weakness Fuel Selloff
U.S. stocks extended their weekly decline, with the S&P 500 and Nasdaq Composite closing at their lowest levels in six months. A sharp rise in crude oil prices and persistent weakness in major technology shares pressured the broader market.
Unity Stock Soars on Upbeat Q1 Forecast and Strategic Divestment Plan
Unity Software's stock jumped 11% to $19.01 following an improved first-quarter outlook and a strategic decision to divest slower-growth advertising and publishing units.
Stocks Slide, Oil Soars as Iran Deadline Extension Fails to Calm Markets
Wall Street declined sharply on Friday, with the S&P 500 and Nasdaq Composite both falling over 0.9%, while Brent crude oil jumped above $110 a barrel after the White House extended a key deadline in the Iran conflict, raising concerns over prolonged inflation and interest rates.
Unity Software Plunges on Weak Q1 Forecast, AI Concerns
Unity Software shares dropped nearly 10% following a weak first-quarter revenue forecast and analyst warnings about competitive threats from artificial intelligence.
Unity Stock Stabilizes After Sharp Guidance Cut, AI Concerns Loom
Unity shares held near $21.41 in premarket trading following a 26% plunge after the company issued weaker-than-expected Q1 revenue guidance. Investors are monitoring demand for its Create tools and advertising segment.
Virgin Galactic Soars 36% on VSS Unity Glide Flights
Virgin Galactic shares jumped 36% on record volume after resuming VSS Unity glide flights, with new spaceship tests targeted for Q3 and a 2027 research mission.
ImmunityBio's Anktiva Expansion Faces FDA Scrutiny with 2027 Decision Date
ImmunityBio's supplemental BLA for Anktiva in papillary-only bladder cancer has been accepted by the FDA, with a decision expected by Jan. 6, 2027. The company's stock traded at $7.76, down 2.8%.
ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy
ImmunityBio announced five U.S. patents protecting its Anktiva-plus-BCG bladder cancer therapy through 2035, and an exclusive supply deal for the Tokyo-172 BCG strain.
ImmunityBio Secures Exclusive US Rights to Japan BCG Strain for Bladder Cancer
ImmunityBio announced exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain for bladder cancer therapy, with FDA discussions planned. Shares closed at $7.97 Friday, down 2.2%.
ImmunityBio Plunges 21% on FDA Warning Over Anktiva Marketing
ImmunityBio shares tumbled 21.1% following an FDA warning letter alleging false or misleading promotional claims about its cancer therapy Anktiva. The drug generated essentially all of the company's $113 million in 2025 revenue.
ImmunityBio Surges on NK-Cell Manufacturing Milestone, Anktiva Expansion Progress
ImmunityBio shares jumped 10.5% Friday following news of a completed scalable manufacturing process for its NK-cell therapy platform and regulatory progress for its drug Anktiva. The company also reported surging 2025 revenue.
ImmunityBio Shares Dip Ahead of Key Business Update Call
ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.